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Abstract
Background: Antiretroviral treatment (ART) options for young children co-infected with HIV and tuberculosis are limited in
resource-poor settings due to limited data on the use of efavirenz (EFV). Using available pharmacokinetic data, an EFV
dosing schedule was developed for young co-infected children and implemented as the standard of care at Macha Hospital
in Southern Province, Zambia. Treatment outcomes inchildren younger than 3 years of age or weighing less than 10 kg
receiving either EFV-based ART plus anti-tuberculous treatment or nevirapine-based (NVP) ART were compared.
Methods: Treatment outcomes were measured in a cohort of HIV-infected children seeking care at Macha Hospital in rural
Zambia from 2007 to 2010. Informationon the diagnosis and treatment of tuberculosis was abstracted from medical records.
Results: Forty-five children treated for tuberculosis initiated an EFV-based regimen and 69 children initiated a NVP-based
regimen, 7 of whom also were treated for tuberculosis. Children receiving both regimens were comparable in age, but
children receiving EFV started ART with a lower CD4+ T-cell percentage and weight-for-age z-score. Children receiving EFV
experienced increases in both CD4+ T-cell percentage and weight-for-age z-score during follow-up, such that levels were
comparable to children receiving NVP after two years of ART. Cumulative survival after 12 months of ART did not differ
between groups (NVP:87%;EFV:80%;p = 0.25). Eleven children experienced virologic failure during follow-up.The adjusted
hazard ratio of virologic failure comparing EFV to NVP was 0.25 (95% CI:0.05,1.24) and 0.13 (95% CI:0.03,0.62) using
thresholds of 5000 and 400 copies/mL, respectively.Five children receiving EFV were reported to have had convulsions after
ART initiation compared to only one child receiving NVP (p = 0.04).
Conclusions: Despite poorer health at ART initiation, children treated for tuberculosis and receiving EFV-based regimens
showed significant improvements comparable to children receiving NVP-based regimens. EFV-based regimens should be
considered for young HIV-infected children co-infected with tuberculosis in resource-limited settings.
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Introduction
The dual burden of human immunodeficiency virus (HIV)
infection and tuberculosis represents a significant threat to the
health of children in sub-Saharan Africa. An estimated 3.4 million
children worldwide are infected with HIV [1], the majority of
whom live in sub-Saharan Africa.In areas of high HIV prevalence,
as many as half of incident pediatric tuberculosis cases occur in
children infected with HIV [2]. Tuberculosis is among the most
common causes of persistent lung disease in HIV-infected children
older than 3 years [3], is one of the leading causes of death from
respiratory illness in HIV-infected children [4], and accelerates
HIV disease progression [5].
Because of the poor prognosis in young children infected with
HIV and tuberculosis, there is no alternative to concurrent
treatment of both infections [6]. Simultaneous initiation of both
therapies increases the risk of immune reconstitution syndrome,
but extensive delays in starting antiretroviral therapy (ART)
should be avoided. Current WHO recommendations for co-
infected children are that ART should be initiated 2–8 weeks after
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starting treatment for tuberculosis [6], and a cohort study
suggested that ART should not be delayed more than 60 days [7].
The optimal antiretroviral regimen for children receiving anti-
tuberculous treatment has not been established. Rifampicin is a
potent inducer of the cytochrome P450 system and hepatic
glucuronidation, resulting in significant reductions in serum levels
of several antiretroviral drugs [8]. The alternative, rifabutin, has
fewer drug interactions but is often not available in most resource-
limited settings, has not undergone formal pharmacokinetic and
safety studies in children, and is associated with corneal deposits
and other ocular toxicity in children [9]. The preferred
antiretroviral regimen for co-administration with rifampicin in
adults and older children is two nucleoside reverse transcriptase
inhibitors (NRTI) plus efavirenz (EFV). For children younger than
3 years of age receiving rifampicin, current WHO recommenda-
tions for antiretroviral therapy include two NRTI plus nevirapine
(NVP) or three NRTI [6]. However, both of these options are
problematic and have been associated with reduced virologic
efficacy compared to other regimens [10,11,12,13].
The product labeling for EFV includes dosages only for children
older than 3 years of age and weighing greater than 10 kg, as EFV
dosing for younger or smaller children had not been established.
The 2006 [14] and 2008 [15] WHO recommendations followed
the weight-band dosing table in product labeling (approximately
15 mg/kg/day). However, EFV clearance is not linearly propor-
tional to weight and data are emerging that higher dosages may be
required in children older than 3 years of age [16,17,18,19].Chil-
dren younger than 3 years of age may require even higher relative
dosages. In the P1021 trial, which assessed the efficacy of a once-
daily regimen containing didanosine, emtricitabine and EFV,
serum EFV levels in children younger than 3 years of age were
within the therapeutic range when given a fixed dosage of 390 mg
(median 47 mg/kg) [20,21], significantly higher than current
recommendations. In the P1070 study, a non-linear weight band
dosing scheme averaging approximately 40 mg/kgwas used in
African and Asian children younger than 3 years of age. Drug
levels in the target range were achieved in the majority of children,
except those with the slow-metabolizer CYP2B6516TT genotype
who had higher drug levels [22].
Given the limited antiretroviral treatment options in resource-
constrained settings for children receiving rifampicin, and the need
to initiate ART as soon as possible to avoid excess morbidity and
mortality, an EFV dosing schedule extrapolated from available
data was developed for the clinical care of young children with
tuberculosis. We assessed the effectiveness of EFV-based regimens
by comparing treatment outcomes between young co-infected
children receiving both anti-tuberculous therapy and EFV-based
ART regimens and young children with and without tuberculosis
receiving NVP-based ART regimens enrolled in an observational
cohort study.
Methods
Ethics Statement
The study was approved by the Ministry of Health of the
Government of Zambia, the Research Ethics Committee of the
University of Zambia and the Institutional Review Board of the
Johns Hopkins Bloomberg School of Public Health. Written
informed consent was obtained from parents or guardians and
assent was obtained from children 8–16 years of age.
Setting and Clinical Care
The study was conducted at the pediatric HIV clinic at Macha
Hospital in rural Southern Province, Zambia. The study setting
and population were described in detail elsewhere [23,24]. Briefly,
Macha Hospital is a district-level referral hospital that has
provided care to over 7500 HIV-infected adults and children
since 2005. HIV care services, including antiretroviral treatment,
are provided through the Government of Zambia’s antiretroviral
treatment program, with support from the President’s Emergency
Plan for AIDS Relief (PEPFAR) through the non-governmental
organization, AIDSRelief. Care and treatment are provided free of
charge by medical doctors and clinical officers. Mothers and
infants are provided drugs to prevent mother to child transmission
(PMTCT) according to WHO guidelines [25]. Children diagnosed
with HIV infectionare determined to be eligible for ART
according to the WHO treatment guidelines [6,14,15]. Standard
ART regimens consist of stavudine or zidovudine plus lamivudine,
and a non-nucleoside reverse transcriptase inhibitor (NVP or
EFV).
Young children suspected of having tuberculosis undergo a
physical examination and chest radiograph. The clinical diagnosis
of tuberculosis is based on the results of these examinations and
the judgment of the health care provider. Children with
tuberculosis are treated with isoniazid (6 months), rifampicin (6
months), and pyrazinamide (2 months). Children treated with
rifampicin and eligible for ART are treated with two NRTI and
EFV. An EFV dosing schedule based on available data
[16,17,18,19,20,21,26]was provided to clinics supported by
AIDSRelief throughout Zambia beginning in 2006 and adopted
as the standard of care atMacha Hospital for young children with
tuberculosis. The schedule included a fixed dosage of 300 mg daily
(using scored 600 mg tablets) for children weighing between 4 and
20 kg.
Young children without tuberculosis and eligible for ART were
treated with two NRTI and NVP. NVP was dosed using the
WHO 2006 dosing recommendations, which included guidance
on induction and maintenance dosing [14].
Study Procedures
Beginning September 2007, HIV-infected children younger
than 16 years of age and seeking care at the pediatric HIV clinic at
Macha Hospital were eligible for enrollment into an observational
cohort study. This report describes a subset of these subjects.
Children were evaluated at study visits approximately every three
months, at which time a questionnaire was administered to obtain
information on demographics, household characteristics and
medical history. The child was examined to measure height and
weight, and a blood specimen was obtained to measure CD4+ T-
cell counts and percentages (Guava Easy CD4 system;Guava
Technologics, Inc., Hayward, CA) and ALT (ReflotronPlusChem-
istry Analyzer and CobasC111;Roche Molecular Systems)as part
of clinical care. Plasma levels of HIV RNA were quantified by
reverse transcriptase polymerase chain reaction assay (Amplicor
HIV-1 Monitor v. 1.5, Roche Molecular Systems; lower limit of
detection of 400 copies/mL) as part of the study. For children
receiving ART, adherence was assessed by pillcounts and syrup
volume measurements. For children who missed study visits, home
visits were attempted to ascertain their status.
Information regarding prior and current diagnosis and treat-
ment of tuberculosis and adverse events while receiving ART were
abstracted from medical records. Adverse events were defined as
any clinical sign or symptomor elevated ALT measure possibly or
probably related to ART. Elevated ALT measures were graded
according to WHO guidelines [6].
Efavirenz-Based ART for Children with HIV and TB
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Study Population
This analysis was restricted to children younger than 3 years of
age or weighing less than 10 kg who were enrolled in the
observational cohort study and initiated ART with a regimen
consisting of two nucleoside analogues plus either EFV or NVP
prior to January 1, 2011 (Figure 1). The group of children
receiving EFV consisted solely of those receiving concurrent
treatment for HIV and tuberculosis. The group of children
receiving NVP included children with and without tuberculosis.
The children with tuberculosis were inadvertently initiated on a
regimen containing NVP and were switched to EFV at the
discretion of the clinic physician or clinical officer. Children
initiating ART with NVP who were subsequently diagnosed with
tuberculosis (n = 4) were excluded. Children were categorized as
receiving an EFV or NVP-based regimen according to their
regimen at initiation or during follow-up.
Study outcomes, including mortality, virologic failure, CD4+ T-
cell percentage, growth and adherence were assessed until May 1,
2011. Children were included in the analysis until they died, were
lost to follow-up or were administratively censored on May 1,
2011. Children whose last study visit occurred more than six
months prior to May 1, 2011 were considered lost to follow-up.
Statistical Analysis
Data were entered in duplicate using EpiInfo (Centers for
Disease Control and Prevention) and analyses were conducted
using SAS for Windows version 9.1 (SAS Institute Inc., Cary, NC)
and STATA, version 9 (StataCorp LP, College Station, TX).
Characteristics of children receiving NVP and EFV at ART
initiation were compared using chi-square tests for binary variables
and Wilcoxon rank sum tests for continuous variables. Severe
immunosuppression was defined by age according to the 2006
WHO treatment guidelines [14]. Weight-for-age (WAZ) z-scores
were calculated based on WHO growth standards [27], and
children with WAZ below 22 were considered underweight.
Children with hemoglobin ,8 g/dL were considered severely
anemic [28]. Use of drugs by the mother or child to prevent
mother to child transmission (PMTCT) was ascertained by
interview and confirmed by review of medical records.If
measurements were not available from the visit at which ART
was initiated, results within 3 months prior to the date of initiation
were used.
Clinical and immunologic outcomes were evaluated among
children with at least one measurement after ART initiation using
longitudinal data analysis. Linear mixed effects models with
random intercept, exchangeable correlation structure and robust
standard error estimation were used. Interaction terms between
EFV and time were included to determine whether trajectories of
the outcomes differed between children receiving EFV or NVP.
For CD4+ T-cell percentage, a spline term was added at 6 months
as trajectories were not linear over time.
Survival after ART initiation was evaluated using Kaplan Meier
survival curves. Survival curves for children receiving NPV and
EFV were compared using the log-rank test. EFV, the primary
exposure of interest, was treated as a time-varying covariate as
three children who initiated ART with NVP and were receiving
anti-tuberculous therapy at ART initiation subsequently switched
to EFV.Cox proportional hazards models were used to compare
the risk of death between children receiving NVP and EFV.
Virologic outcomes also were evaluated. The proportion of
children with viral suppression, defined as a viral load below the
limit of detection (400 copies/mL), was calculated for each visit
after ART initiation and compared between children receiving
NPV and EFV using chi-square tests. As for mortality, virologic
failure was evaluated using Kaplan Meier survival curves and Cox
proportional hazards models with EFV treated as a time-varying
covariate. Virologic failure was defined according to WHO
guidelines [6] as at least two viral load measurements .5000 cop-
ies/mL among children who received at least six months of ART,
and was defined on the date of the second measurement. An
alternate definition of virologic failure was also assessed using a
cut-off of $400 copies/mL. Children entered the analysis on their
first viral load measure at or beyond 6 months of ART and were
Figure 1. Study flowchart. ART: antiretroviral treatment; ATT: anti-tuberculous treatment; EFV: efavirenz; FU: follow-up; LTFU: loss to follow-up;
NVP: nevirapine.
doi:10.1371/journal.pone.0055111.g001
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included until they experienced virologic failure, were lost to
follow-up or were administratively censored on May 1, 2011.
For all analyses, characteristics known to be associated with the
outcome from the published literature or found to be associated
with the outcome (p,0.10) in the crude models were considered
for inclusion in the multivariable models.
Caregivers were instructed to bring all unused medications at
each visit and adherence was measured by pill count or
measurement of liquids for each drug prescribed. Adherence
measures were capped at 100%. For children taking more than
one drug, the adherence percentage of the drug to which the
patient was least adherent was used. Children were defined as
adherent using two thresholds, depending upon whether they took
more than 90% or 95% of drugs prescribed. The proportions of
children receiving NVP or EFV who were adherent at each visit
and at all visits were compared using chi-square tests.
Results
Characteristics of the Study Population
Between September 2007 and December 2010, 114 children
younger than 3 years of age or weighing less than 10 kg initiated
antiretroviral treatment and were eligible for analysis, including 45
children receiving an EFV-based regimen and 69 children
receiving a NVP -based regimen.
Among children receiving EFV, the median time between the
start of anti-tuberculous therapy and initiation of ART was 1.9
months (IQR: 1.0, 2.4; range 0.6–5.4). Twenty-eight (62%)
children started ART during the intensive phase of anti-
tuberculous therapy (within the first two months), and 17 (38%)
during the continuation phase (within 2–6 months; median 2.4
months). Among children receiving NVP, five children were
previously treated for tuberculosis but started ART after
completion of anti-tuberculous therapy. Seven children receiving
NVP were also receiving anti-tuberculous therapy at ART
initiation (three initiated ART during the intensive phase and
four during the continuation phase) and three subsequently
switched to EFV (time to switch: 0.4, 0.9, and 1.3 months after
ART initiation).
The median age at ART initiation was 17.4 months for children
receiving EFV and 20.2 months for children receiving NVP, and
the majority of children were female (Table 1). Few children
receiving either EFV or NVP had previous exposure to
antiretroviral drugs as part of the PMTCT program and the
majority of children received an ART backbone of stavudine and
lamivudine. Children receiving EFV were significantly more likely
to be classified as WHO stage 3 or 4, and have a lower CD4+ T-
cell percentage, weight and WAZ. They were marginally more
likely to have a lower hemoglobin level (Table 1).
At the end of follow-up, 8 (12.1%) children receiving NVP and
10 (20.8%) receiving EFV died (p = 0.21), and 5 (7.6%) children
receiving NVP and one (2.1%) receiving EFV transferred to
another clinic (p = 0.19). No child was lost to follow-up. The
median duration of follow-up on ART was comparable between
groups, with 13.4 months (IQR: 5.9, 27.0) of follow-up for children
receiving NVP and 16.7 months (IQR: 8.2, 23.3) for children
receiving EFV (p= 0.68).
Clinical and Immunologic Outcomes
Children receiving EFV initiated ART with a significantly lower
WAZ than children receiving NVP, and experienced significantly
greater increases in WAZ during follow-up (NVP: mean change
+0.1, standard deviation [SD] 1.0; EFV: +1.8, SD 1.6, at 12
months; p,0.0001) (Figure 2). Results of the longitudinal data
analysis showed significantly different trajectories of WAZ between
the two groups of children, with children receiving EFV
experiencing a significantly greater increase in WAZ per month,
such that they were able to catch-up to children receiving
NVPwithin two years of ART (Table 2).
Children receiving EFV also initiated ART with a significantly
lower CD4+ T-cell percentage than children receiving NVP, but
experienced comparable increases in CD4+ T-cell percentage
during follow-up (NVP: +16.9%, SD 8.4; EFV: +15.0%, SD 9.6 at
12 months; p= 0.47) (Figure 3).Results of the longitudinal data
analyses showed significantly different trajectories of CD4+ T-cell
percentages between the two groups of children. Among children
receiving NVP, CD4+ T-cell percentage increased rapidly in the
first 6 months of ART and then stabilized for the duration of
follow-up (Table 2). In contrast, among children receiving EFV,
CD4+ T-cell percentage increased more slowly in the first 6
months but continued to increase for the duration of follow-up,
such that levels were comparable among all children after two
years of ART (Table 2).
Virologic Failure
Within the first 3 months of ART, the majority of children
receiving NVP (80.7%) and EFV (87.5%; p= 0.50) achieved
virologic suppression. The majority of children maintained
virologic suppression at 12 (NVP: 78.8%; EFV: 91.7%; p= 0.19)
and 24 months (NVP: 68.4%; EFV: 77.8%; p= 0.61) of ART.
Virologic failure was assessed among the 72 children (40 receiving
NVP and 32 receiving EFV) with at least two viral load measures
at or beyond 6 months of ART. Four children receiving EFV
(12.5%) and 7 children receiving NVP (17.5%; p= 0.56) experi-
enced virologic failure (Figure 4; log-rank test: p = 0.63; Table S1).
None of the children receiving NVP who experienced virologic
failure were also receiving anti-tuberculous therapy at ART
initiation.The risk of virologic failure was not significantly different
among children receiving EFV compared to children receiving
NVP (hazard ratio [HR]: 0.73; 95% CI: 0.21, 2.49). After
adjusting for CD4+ T-cell percentage and WAZ at ART initiation,
receipt of PMTCT, and number of viral load measures, the risk of
virologic failure was lower among children receiving EFV
(adjusted HR: 0.25; 95% CI: 0.05, 1.24; Table 3), although this
result was not statistically significant. When virologic failure was
defined by two viral load measures above the lower limit of
detection (400 copies/mL) after 6 months of ART, the percentage
of children with virologic failure was 15.6% among children
receiving EFV compared to 22.5% among children receiving NVP
(adjusted HR: 0.13; 95% CI: 0.03, 0.62; Table 3).
Mortality
Eighteen deaths were recorded among study children (NVP:
12.1%; EFV: 20.8%; p= 0.21). Among children who died, the
median time to death after ART initiation was 1.6 months (IQR:
1.1, 4.3) among children receiving NVP and 3.4 months (IQR:
0.9, 7.3) among children receiving EFV (p= 0.41). Cumulative
survival was high at 6 months (NVP: 89%, 95% CI: 79, 95; EFV:
87%, 95% CI: 74, 94) and 12 months (NVP: 87%, 95% CI= 76,
93; EFV: 80%, CI= 65, 89) after initiating ART and did not differ
significantly between groups (Figure 5; log-rank test: p = 0.25). The
mortality rate per 100 person-years was 8.71 (95% CI: 4.36, 17.41)
among children receiving NVP and 15.81 (95% CI: 8.51, 29.38)
among children receiving EFV. The risk of mortality was non-
significantly higher among children receiving EFV (HR: 1.72;
95% CI: 0.68, 4.36). After adjusting for CD4+ T-cell percentage,
WAZ and hemoglobin at ART initiation, no difference in
mortality was observed (adjusted HR: 1.00; 95% CI: 0.30, 3.31).
Efavirenz-Based ART for Children with HIV and TB
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Adherence
The percentage of children who took more than 90% of their
dispensed medication at all visits, verified by pill count and syrup
measurement, was 56% for children receiving NVP and 46% for
children receiving EFV (p= 0.35). No significant differences were
observed in adherence between children receiving NVP or EFV at
any of the study visits (Table S2). Similar results were obtained
Table 1. Characteristics of children receiving nevirapine and efavirenz at ART initiation.
N (NVP/EFV) Children receiving NVP Children receiving EFV p-value
Age in months: median (IQR) 69/45 20.2 (11.0, 27.1) 17.4 (13.6, 22.6) 0.36
Male: n (%) 69/45 31 (44.9) 17 (37.8) 0.45
Mother and/or child received drugs to prevent mother-to-child
transmission of HIV (confirmed or self-reported): n (%)
69/45 6 (8.7) 6 (13.3) 0.21
WHO stage 3 or 4: n (%) 32/36 25 (78.1) 36 (100.0) 0.01
CD4%: median (IQR) 64/41 18.5 (15.7, 25.2) 14.2 (9.8, 20.7) 0.007
Severe immunosuppressiona: n (%) 41 (64.1) 29 (70.7) 0.48
Hemoglobin (g/dL): median (IQR) 66/44 9.4 (8.6, 10.3) 9.0 (7.9, 9.8) 0.08
Weight (kg): median (IQR) 69/45 8.8 (7.2, 10.0) 7.2 (6.2, 8.6) 0.005
Weight-for-age z-score: median (IQR) 69/45 21.7 (22.8, 20.5) 22.7 (23.6, 21.8) 0.001
Underweightb: n (%) 32 (46.4) 31 (68.9) 0.02
BCG vaccination scar present: n (%) 69/45 65 (94.2) 41 (91.1) 0.53
Regimen: n (%) 69/45
Stavudine/lamivudine 59 (85.5) 33 (73.3)
Zidovudine/lamivudine 9 (13.0) 10 (22.2)
Abacavir/lamivudine 1 (1.5) 2 (4.4) 0.25
BCG: Bacillus Calmette-Guerin; EFV: efavirenz; IQR: interquartile range; NVP: nevirapine; WHO: World Health Organization.
aSevere immunosuppression defined by age according to the 2006 WHO treatment guidelines.
bUnderweight defined as weight-for-age z-score less than 22.
doi:10.1371/journal.pone.0055111.t001
Figure 2. Mean weight-for-age z-score (95% confidence interval) after ART initiation by regimen.
doi:10.1371/journal.pone.0055111.g002
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when adherence was defined as taking more than 95% of
dispensed medication.
Adverse events Associated with Antiretroviral Therapy
None of the children discontinued EFV or NVP because of
adverse events. Five children receiving EFV were reported to have
had convulsions after ART initiation compared to only one child
receiving NVP (p= 0.04). Convulsions were reported 2 weeks to 9
months after ART initiation. No children were prescribed
antiepileptic drugs. The dose of EFV was reduced in one child
whose caregiver reported intermittent seizures at one clinic visit 3
months after ART initiation.The child was reported to have had
no more convulsions, was switched to NVP after completing anti-
tuberculous treatment, and died at home five months later with
symptoms of gastroenteritis and pneumonia. In the other five
children, including one child with convulsions reported before and
after EFV initiation, three children whose convulsions were
suspected to be related to febrile episodes (2 receiving EFV, 1
Table 2. Changes in CD4+ T-cell percentages and weight-for-age z-scores after ART initiation by regimen.
Crude Adjusted
Children
receiving NVP
Children
receiving EFV p-value
Children
receiving NVP
Children
receiving EFV p-value
CD4+ T-cell percentage (CD4%) a b
CD4% at ART initiation (SE) 22.61 (1.09) 18.42 (1.08) 0.006 25.41 (1.93) 22.79 (2.01) 0.12
Increase in CD4% per month in first 6 months of ART (SE) 2.04 (0.17) 1.49 (0.21) 0.05 2.04 (0.18) 1.51 (0.21) 0.06
Increase in CD4% per month after 6 months of ART (SE) 20.11 (0.10) 0.37 (0.10) 0.001 20.11 (0.10) 0.36 (0.11) 0.001
Weight-for-age z-score (WAZ) a c
WAZ at ART initiation (SE) 21.25 (0.17) 22.04 (0.21) 0.005 21.07 (0.25) 21.41 (0.25) 0.009
Increase in WAZ per month (SE) 0.02 (0.01) 0.07 (0.02) 0.003 0.02 (0.01) 0.07 (0.02) 0.008
EFV: efavirenz; NVP: nevirapine; SE: standard error.
aResults shown are from linear mixed effects models with random intercept, exchangeable correlation structure and robust standard error estimation. Interaction terms
between EFV and time were included to determine whether trajectories of the outcomes differed between children receiving EFV or NVP. For CD4+ T-cell percentage, a
spline term was added at 6 months as trajectories were not linear over time.
bAdjusted for hemoglobin, weight-for-age z-score, and age at ART initiation.
cAdjusted for hemoglobin, CD4+ T-cell percentage, weight-for-age z-score, and age at ART initiation.
doi:10.1371/journal.pone.0055111.t002
Figure 3. Mean CD4+ T-cell percentage (95% confidence interval) after ART initiation by regimen.
doi:10.1371/journal.pone.0055111.g003
Efavirenz-Based ART for Children with HIV and TB
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e55111
receiving NVP), and one child with suspected HIV encephalop-
athy, treatment was continued without modification and the
seizures did not recur during the period of observation. No other
differences in clinical symptoms were found between children
receiving EFV and NVP. Twenty-two children had transiently
elevated alanine aminotransferase levels (ALT $62.5 U/L [6])
during follow-up: 29.4% of children receiving NVP and 19.4% of
children receiving EFV (p= 0.29). The median time from ART
initiation to the first episode of elevated ALT was 30 weeks (IQR:
26, 49; range 2–129) among children receiving NVP and 49 weeks
(IQR: 28, 76; range: 23–76) among the children receiving EFV.
All episodes were grade 1 or 2 events and no child required a
change or discontinuation of treatment as a result of the elevated
ALT.
Discussion
Despite poorer health at ART initiation, children younger than
3 years of age who were treated for tuberculosis and received an
EFV-based ART regimen showed significant improvements in
clinical, immunological and virologic outcomes, comparable to
young children receiving a NVP-based regimen.
To our knowledge, no studies of the virologic efficacy of EFV-
based regimens have been conducted among children younger
than 3 years of age to support recommendations for its use in this
population. However, use of EFV-based regimens for young
children co-infected with tuberculosis would be a useful alternative
treatment strategy given the limited treatment options available.-
WHOcurrently recommends that HIV-infected infants and
children younger than 3 years of age and treated for tuberculosis
receive either two NRTI plus NVP or three NRTI [6]. However,
there are significant drawbacks to both options. When co-
administered with rifampicin, studies have found NVP levels to
Figure 4. Cumulative probability of virologic failure after 6 months of ART by regimen.
doi:10.1371/journal.pone.0055111.g004
Table 3. Crude and Adjusted models for virologic failure.
Virologic failure threshold of 5000 copies/mL Virologic failure threshold of 400 copies/mL
Crude HR (95% CI) Adjusted a HR (95% CI) Crude HR (95% CI) Adjusted a HR (95% CI)
EFV 0.73 (0.21, 2.49) 0.25 (0.05, 1.24) 0.72 (0.24, 2.15) 0.13 (0.03, 0.62)
CD4% at ART initiation (per 5) 0.83 (0.54, 1.28) 0.60 (0.34, 1.06) 0.76 (0.51, 1.13) 0.53 (0.31, 0.91)
WAZ at ART initiation
$ 22 1 1 1 1
22.1 to 23 0.56 (0.11, 2.81) 0.56 (0.11, 2.93) 0.40 (0.08, 2.00) 0.37 (0.07, 1.95)
, 23 1.47 (0.37, 5.88) 4.21 (0.69, 25.69) 1.81 (0.55, 5.92) 7.48 (1.36, 41.01)
Receipt of PMTCT 2.05 (0.44, 9.50) 8.37 (0.90, 78.30) 1.28 (0.28, 5.91) 9.61 (1.03, 89.39)
ART: antiretroviral therapy; EFV: efavirenz; HR: hazard ratio; PMTCT: prevention of mother-to-child transmission; WAZ: weight-for-age z-score.
aAdditionally adjusted for number of viral load measures.
doi:10.1371/journal.pone.0055111.t003
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be significantly reduced in both adults [29,30,31] and children
[32,33], thereby increasing the likelihood of drug resistance and
virologic failure. Increasing the dose of NVP when co-adminis-
tered with rifampicin may achieve target drug levels [31,34], but
may also lead to unacceptable toxicity and discontinuation rates
[14,34].There is also increasing evidence that NVP is inferior to
EFV and other regimens in terms of virologic efficacy among
adults and children, with [35,36] and without [11,12,13,37]tuber-
culosis. Regimens comprising 3 NRTI are also problematic, as
they have been associated with high rates of virologic failure in
both children [10] and adults [38], particularly when baseline viral
loads exceed 100,000 copies RNA/mL [39,40]. In co-infected
children, who are likely to have high baseline viral loads, the risk of
such failure is likely to be unacceptably high.
An alternative treatment option not endorsed by the WHO for
young children with tuberculosis is a regimen consisting of 2 NRTI
plus ritonavir-boosted lopinavir (LPV/r). As with NVP, lopinavir
levels are significantly reduced by rifampicin [8]. Doubling the
dose of LPV/r to overcome this pharmacokinetic interaction has
resulted in high toxicity and discontinuation rates [41], or
persistently inadequate serum concentrations [42].One small
study in South African children found that increasing the dose
of ritonavir to achieve a LPV/r ratio of 1:1 resulted in acceptable
pharmacokinetics for most children with little reported toxicity
[43]. However, ritonavir as a single agent is not yet widely
available in many resourced-limited settings and is associated with
poor tolerability [44].
Consequently, there is need for alternative treatment strategies
for young children with tuberculosis and data to support their use.
The dosing schedule for EFV in Zambia was developed based on
available pharmacokinetic data [16,17,18,19,20,21,26] and was
independent of the observational cohort study. Children with
tuberculosis receiving EFV-based regimens in this study achieved
good clinical and immunologicoutcomes that were comparable to
children receiving NVP-based regimens, most of whom were not
co-infected with tuberculosis. Similar to studies in adults [35,36],
our findings suggest that children receiving EFV-based regimens
were more likely to achieve virologic suppression compared to
children receiving NVP-based regimens.Children with tuberculo-
sis receiving EFV-based regimens had higher mortality compared
to children receiving NVP-based regimens, although the difference
was not statistically significant within the limited power conferred
by the few number of deaths. This difference was presumably due
to the poorer clinical and immunologic state of the children with
tuberculosis, and was not observed after adjusting for these factors.
In other studies, co-infection with tuberculosis was associated with
increased mortality in children receiving ART [45].
All children tolerated EFV and, in contrast to other studies
[20,46,47,48,49], no child discontinued use during the period of
observation. Due to the young age of the study population,
symptoms were assessed by caregiver report and many symptoms
possibly related to EFV use, including loss of concentration, sleep
disorders, or psychotic reactions, were difficult to evaluate.
Caretakers and guardians were asked about symptoms and
complaints in routine clinical care but not specifically about
possible adverse events related to ART or EFV, which may have
resulted in underreporting of side effects. However, if adverse
events did occur and were missed by the guardian and healthcare
worker, they were likely mild and transient. ALT was the only
laboratory measure assessed during follow-up; however, the
relevance of elevated ALT measurements is unclear as they
occurred without symptoms and only sporadically in most
children.
The reports by parents or caretakers of a seizure in five of the
children receiving EFV and one receiving NVP are concerning but
a causal association is difficult to establish in this observational
study. In preclinical studies of EFV, convulsions were seen in
monkeys with high EFV levels [50]. Only a single case of seizures
related to EFV use in children has been reported [51] in a child
who developed absence seizures in association with high levels of
EFV and a slow-metabolizer genotype. All children with seizures
reported here continued their drug (one with EFV dose reduction)
without further report of seizures, and given the limited diagnostics
available, the contribution of ART to the seizures is difficult to
Figure 5. Cumulative survival after ART initiation by regimen.
doi:10.1371/journal.pone.0055111.g005
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determine. The greater frequency of the CYP2B6 TT genotype
associated with slow metabolism in Africans [52], and the median
half-life of only 11.4 hours in young children that makes relatively
large dosages necessary to achieve adequate trough levels, means
that some children will have transient high drug levels. Shortening
the dosing interval to 12 hours in small children is a potential
strategy to avoid high peak levels that might lead to toxicity.
Although informative and encouraging, this study has several
limitations. This was an observational cohort study and the
diagnosis of tuberculosis and decisions regarding ART regimens
were made by the treating clinicians. These decisions were
independent of the observational cohort study from which data for
this report were abstracted, and there was no provision for
pharmacokinetic studies or comprehensive safety monitoring.
With the implementation of the EFV dosing schedule at the
HIV clinic, children with tuberculosis were prescribed an EFV-
based ART regimen. Consequently, the characteristics of the
children receiving EFV-and NVP-based ART regimens were
different, as the majority of children receiving NVP-based
regimens were not co-infected with tuberculosis. Attempts were
made to account for these differences in the analysis but measures
of all potentially relevant characteristics were not available. The
diagnosis of tuberculosis in children is difficult and radiographic or
microbiologic tests were not performed on all children in the
study. We attempted to address this issue by excluding children
diagnosed with tuberculosis after ART initiation but could not
account for children with undiagnosed tuberculosis during the
study period. Additional limitations include the small sample size,
which limited the power to detect statistically significant differ-
ences between the two groups (particularly for virologic outcomes),
the relatively short duration of follow-up, and, as previously
described, the difficulties in measuring EFV-related side effects.
Conclusions
This is the first study to demonstrate that EFV can be used
effectively in young HIV-infected children with tuberculosis.
Additional studies will be required to validate and optimize an
EFV dosing strategy for young children co-infected with tubercu-
losis. Given the increasing number of young HIV-infected children
starting ART in sub-Saharan Africa, the high burden of
tuberculosis, the limited treatment options in this region, and the
limited virologic efficacy of NVP, use of EFV in young children
should be considered.
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